Reddy Holding GmbH
3 products tracked · names used in filings: Reddy Holding GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 17 Nov 2025🇪🇺 EU approval (EC decision)
Xbonzy (denosumab) approved in the EU
Marketing authorisation to Reddy Holding GmbH; Biosimilar · source
Mon 17 Nov 2025🇪🇺 EU approval (EC decision)
Acvybra (denosumab) approved in the EU
Marketing authorisation to Reddy Holding GmbH; Biosimilar, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Xbonzy denosumab | Authorised | 2025-11-17 |
| 🇪🇺 | Acvybra denosumab | Authorised | 2025-11-17 |
| 🇪🇺 | Ituxredi rituximab | Authorised | 2024-09-19 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.